Georgy Egorov

Georgy Egorov has diverse work experience in various industries and roles. Georgy currently holds the position of Chief Financial Officer at ZeroAvia since 2022. Prior to this, they served as the Chief Financial Officer at Vaccitech / Barinthus Bio, a biotechnology company specializing in T cell vaccines and immunotherapy, from 2020 to 2022. Georgy also worked as the Chief Financial Officer and Board Member/Executive Director at Exscientia, a leading drug design biotechnology company, from 2018 to 2020. Georgy has held positions in other esteemed organizations such as Vendigo, Samlino Group, UBS, Goldman Sachs, EBRD, and PwC, where they contributed their expertise in finance, capital markets, and corporate planning.

Georgy Egorov has a Master of Studies (MSt) degree in Social Innovation from the University of Cambridge. Georgy also has a Bachelor's and Master's degree (BSc/MSc) in Finance & Math from the Plekhanov Russian University of Economics. In addition to their formal education, they have obtained certifications in Drug Discovery from Coursera, a Certificate in Investments (FCA) from the Chartered Institute for Securities & Investment (CISI), and is a Qualified Chartered Certified Accountant from ACCA. Georgy also participated in a foreign student exchange program at De Haagse Hogeschool/The Hague University of Applied Sciences, studying Business Management.